Strategies for preventing type 2 diabetes: An update for clinicians

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 5, 2013, Pages 242-261

  Khavandi, Kaivan ^a   Amer, Halima ^b   Ibrahim, Bashar ^c   Brownrigg, Jack ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiometabolic; Cardiovascular disease; Diabetes; Metabolic syndrome; Obesity; Preventive medicine; Renin angiotensin aldosterone system (RAAS); Vascular disease; Weight loss

Indexed keywords

ACARBOSE; AMFEBUTAMONE; AMLODIPINE; CANDESARTAN HEXETIL; DOXAZOSIN; EXENDIN 4; GLIBENCLAMIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; LISINOPRIL; LORCASERIN; METFORMIN; NALTREXONE; NATEGLINIDE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAVASTATIN; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TROGLITAZONE; VALSARTAN; VOGLIBOSE;

AGITATION; ANXIETY; BARIATRIC SURGERY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEFECATION DISORDER; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; FECES INCONTINENCE; FOLLOW UP; HEADACHE; HEART RATE; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84890037580     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313494986     Document Type: Article

References (170)

1. Abdul-Ghani M. Tripathy D. de Fronzo R. (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 29, 1130–1139.
2. Adams T. Gress R. Smith S. Halverson R. Simper S. Rosamond W. et al. (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357: 753–761.
3. Akbas F. Gasteyger C. Sjodin A. Astrup A. Larsen T. (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10: 58–67.
4. Alberti K. (1996) The clinical implications of impaired glucose tolerance. Diabet Med 13: 927–937.
5. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967–1975.
6. American Diabetes Association (2010) Standards of medical care in diabetes 2010. Diabetes Care 33(Suppl. 1): S11–S61.
7. Ametov A. Barinov A. Dyck P. Hermann R. Kozlova N. Litchy W. et al. (2003) The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the Sydney trial. Diabetes Care 26: 770–776.
8. Arguelles Sarmiento J. Bernal Velázquez H. Andiyo Vasquez L. (2005) Duodeno-jejunal exclusion in the treatment of type 2 diabetes mellitus: report on the first 8 non-obese or morbidly obese diabetic patients. Obes Surg 15: abstract 727.
9. Astrup A. Rossner S. van Gaal L. Rissanen A. Niskanen L. Al Hakim M. et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606–1616.
10. Balion C. Raina P. Gerstein H. Santaguida P. Morrison K. Booker L. et al. (2007) Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin Chem Lab Med 45: 1180–1185.
11. Batterham R. Cowley M. Small C. Herzog H. Cohen M. Dakin C. et al. (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418: 650–654.
12. Benjamin S. Valdez R. Geiss L. Rolka D. Narayan K. (2003) Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 26: 645–649.
13. Bonds D. Miller M. Bergenstal R. Buse J. Byington R. Cutler J. et al. (2010) The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340: b4909.
14. Bosch J. Yusuf S. Gerstein H. Pogue J. Sheridan P. Dagenais G. et al. (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551–1562.
15. Braga M. Leiter L. (2009) Role of renin–angiotensin system blockade in patients with diabetes mellitus. Am J Cardiol 104: 835–839.
16. British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society and Stroke Association (2005) JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl. 5): v1–v52.
17. Buchanan T. Xiang A. Peters R. Kjos S. Marroquin A., Goico, J.et al. 2002. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796–2803.
18. Buchwald H. Avidor Y. Braunwald E. Jensen M. Pories W. Fahrbach K. Schoelles K. (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292: 1724–1737.
19. Buchwald H. Estok R. Fahrbach K. Banel D. Jensen M. Pories W. et al. (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122: 248–256 e5.
20. Buijsse B. Simmons R. Griffin S. Schulze M. (2011) Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 33: 46–62.
21. Buse J. Ginsberg H. Bakris G. Clark N. Costa F. Eckel R. et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115: 114–126.
22. Califf R. Boolell M. Haffner S. Bethel M. McMurray J. Duggal A. et al. (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 156: 623–632.
23. Chaldakov G. Fiore M. Tonchev A. Dimitrov D. Pancheva R. Rancic G. et al. (2007) Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight. Curr Pharm Des 13: 2176–2179.
24. Chelikani P. Haver A. Reeve J. Jr. Keire D. Reidelberger R. (2006) Daily, intermittent intravenous infusion of peptide YY(3–36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290: R298–R305.
25. Chelikani P. Haver A. Reidelberger R. (2005 a) Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288: R1695–R1706.
26. Chelikani P. Haver A. Reidelberger R. (2005 b) Intravenous infusion of peptide YY(3–36) potently inhibits food intake in rats. Endocrinology 146: 879–888.
27. Cheng D. (2005) Prevalence, predisposition and prevention of type II diabetes. Nutr Metab 2: 29.
28. Chiasson J. Josse R. Gomis R. Hanefeld M. Karasik A. Laakso M. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.
29. Chiellini C. Rubino F. Castagneto M. Nann I.G. Mingrone G. (2009) The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI < 35 kg/m2. Diabetologia 52: 1027–1030.
30. Consensus Development Conference Panel (1991) NIH conference: gastrointestinal surgery for severe obesity. Ann Intern Med 115: 956–961.
31. Cooper-Dehoff R. Gong Y. Handberg E. Bavry A. Denardo S. et al. (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304: 61–68.
32. Cowie C. Rust K. Ford E. Eberhardt M. Byrd-Holt D. et al. (2009) Full accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. Diabetes Care 32: 287–294.
33. Cushman W. Evans G. Byington R. Goff D. Jr. Grimm R. Jr. Cutler J. Simons-Morton D. et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585.
34. Dahl C. Allen M. Urie P. Hopkins P. (2008) Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 6: 34.
35. Damci T. Yalin S. Balci H. Osar Z. Korugan U. Ozyazar M. et al. (2004) Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 27: 1077–1080.
36. Deacon C. Johnsen A. Holst J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952–957.
37. de Fronzo R. (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773–795.
38. de Fronzo R. Abdul-Ghani M. (2011) Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96: 2354–2366.
39. de Fronzo R. Tripathy D. Schwenke D. Banerji M. Bray G. Buchanan T. et al. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364: 1104–1115.
40. Despres J. Golay A. Sjostrom L. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121–2134.
41. Di Marzo V. Matias I. (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585–589.
42. Dixon J. O'Brien P. Playfair J. Chapman L. Schachter L. Skinner S. et al. (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299: 316–323.
43. Durrington P. (2007) Hyperlipidaemia Diagnosis and Management. London: Hodder Arnold.
44. Dyson P. Kelly T. Deakin T. Duncan A. Frost G. Harrison Z. et al. (2011) Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med 28: 1282–1288.
45. Elliott W. Meyer P. (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207.
46. Emerging Risk Factors Collaboration, Seshasai S. Kaptoge S. Thompson A. Di Angelantonio E. Gao P. et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829–841.
47. Engeli S. Bohnke J. Feldpausch M. Gorzelniak K. Janke J. Batkai S. et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838–2843.
48. Evans J. (1995) Causes of blindness and partial sight in England and Wales 1990–1991. Studies on Medical and Population Subjects Reports No. 57. London: HMSO.
49. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20, 1183–1197.
50. Ferrannini E. Gastaldelli A. Iozzo P. (2011) Pathophysiology of prediabetes. Med Clin North Am 95: 327–339, vii–viii.
51. Ferrannini E. Nannipieri M. Williams K. Gonzales C. Haffner S. Stern M. (2004) Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 53: 160–165.
52. Forouhi N. Luan J. Hennings S. Wareham N. (2007) Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med 24: 200–207.
53. Freeman D. Norrie J. Sattar N. Neely R. Cobbe S. Ford I. et al. 2001. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357–362.
54. Gadde K. Allison D. Ryan D. Peterson C. Troupin B. Schwiers M. et al. (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341–1352.
55. Gerstein H. Santaguida P. Raina P. Morrison K. Balion C. Hunt D. et al. (2007) Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 78: 305–312.
56. Gerstein H. Yusuf S. Bosch J. Pogue J. Sheridan P. Dinccag N. et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096–1105.
57. Graham I. Atar D. Borch-Johnsen K. Boysen G. Burell G. Cifkova R. et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14(Suppl. 2): S1–113.
58. Greenway F. Fujioka K. Plodkowski R. Mudaliar S. Guttadauria M. Erickson J. et al. (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376: 595–605.
59. Gregg E. Cheng Y. Cadwell B. Imperatore G. Williams D. Flegal K. et al. (2005) Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 293: 1868–1874.
60. Haffner S. Lehto S. Ronnemaa T. Pyorala K. Laakso M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234.
61. Hemmingsen B. Lund S. Gluud C. Vaag A. Almdal T. Hemmingsen C. et al. (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898.
62. Herlihy O. Morris R. Karunakaran S. Holman R. (2000) Sulfonylurea therapy over six years does not delay progression to diabetes. Diabetologia 43: abstract A73.
63. Hoffman-Snyder C. Smith B. Ross M. Hernandez J. Bosch E. (2006) Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 63: 1075–1079.
64. Holman R. Blackwell L. Stratton I. Manley S. Tucker L. Frighi V. (2003) Six-year results from the Early Diabetes Intervention Trial. Diabet Med 20: abstract S15.
65. Holman R. Haffner S. McMurray J. Bethel M. Holzhauer B. Hua T. et al. (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362: 1463–1476.
66. Hopper I. Billah B. Skiba M. Krum H. (2011) Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 18: 813–823.
67. Hotta N. Kawamori R. Atsumi Y. Baba M. Kishikawa H. Nakamura J. et al. (2008) Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 25: 818–825.
68. Ilanne-Parikka P. Eriksson J. Lindstrom J. Peltonen M. Aunola S. et al. (2008) Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 31: 805–807.
69. International Diabetes Federation (2012) The global burden. In: IDF Diabetes Atlas, 5th ed. Brussels: International Diabetes Federation. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden (accessed 1 May 2013).
70. International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 32: 1327–1334.
71. James W. Astrup A. Finer N. Hilsted J. Kopelman P. Rossner S. et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119–2125.
72. James W. Caterson I. Coutinho W. Finer N. van Gaal L. Maggioni A. et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905–917.
73. Kahn S. Haffner S. Heise M. Herman W. Holman R. Jones N. et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443.
74. Kawamori R. Tajima N. Iwamoto Y. Kashiwagi A. Shimamoto K. Kaku K. (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373: 1607–1614.
75. Keen H. Jarrett R. Ward J. Fuller J. (1973) Borderline diabetics and their response to tolbutamide. Adv Metab Disord 2(Suppl. 2): 521–531.
76. Kelley D. Kuller L. McKolanis T. Harper P. Mancino J. Kalhan S. (2004) Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27: 33–40.
77. Kjeldsen S. Julius S. Mancia G. McInnes G. Hua T. Weber M. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24: 1405–1412.
78. Knowler W. Barrett-Connor E. Fowler S. Hamman R. Lachin J. Walker E. et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.
79. Knowler W. Bennett P. Hamman R. Miller M. (1978) Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 108: 497–505.
80. Knowler W. Fowler S. Hamman R. Christophi C. Hoffman H. Brenneman A. et al. (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374: 1677–1686.
81. Knowler W. Hamman R. Edelstein S. Barrett-Connor E. Ehrmann D. Walker E. et al. (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150–1156.
82. Knudsen L. Nielsen P. Huusfeldt P. Johansen N. Madsen K. Pedersen F. et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43: 1664–1669.
83. Kohner E. Aldington S. Stratton I. Manley S. Holman R. Matthews D. et al. (1998) United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116: 297–303.
84. Le Roux C. Aylwin S. Batterham R. Borg C. Coyle F. et al. (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243: 108–114.
85. Leiter L. Lewanczuk R. (2005) Of the renin–angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18: 121–128.
86. Li G. Zhang P. Wang J. Gregg E. Yang W. Gong Q. et al. (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371: 1783–1789.
87. Liao D. Shofer J. Boyko E. McNeely M. Leonetti D. Kahn S. et al. (2001) Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care 24: 39–44.
88. Ligresti A. Petrosino S. Di Marzo V. (2009) From endocannabinoid profiling to ’endocannabinoid therapeutics’. Curr Opin Chem Biol 13: 321–331.
89. Lily M. Godwin M. (2009) Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 55: 363–369.
90. Lindholm L. Ibsen H. Borch-Johnsen K. Olsen M. Wachtell K. Dahlof B. et al. (2002) Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20: 1879–1886.
91. Lithell H. Hansson L. Skoog I. Elmfeldt D. Hofman A. Olofsson B. et al. (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886.
92. Malik R. Williamson S. Abbott C. Carrington A. Iqbal J. Schady W. et al. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352: 1978–1981.
93. Mason C. Hanson R. Knowler W. (2007) Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes 56: 2054–2061.
94. Medeiros M. Turner A. (1994) Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 134, 2088–2094.
95. Molitch M. de Fronzo R. Franz M. Keane W. Mogensen C. Parving H. et al. (2004) Nephropathy in diabetes. Diabetes Care 27(Suppl. 1): S79–S83.
96. Moore L. Visioni A. Wilson P. D'Agostino R. Finkle W. Ellison R. (2000) Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? Epidemiology 11: 269–273.
97. Nathan D. Buse J. Davidson M. Ferrannini E. Holman R. Sherwin R. et al. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52: 17–30.
98. Nathan D. Davidson M. de Fronzo R. Heine R. Henry R. Pratley R. et al. (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30: 753–759.
99. National Institute for Health and Clinical Excellence (2008) Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 66. London: National Institute for Health and Clinical Excellence.
100. National Institute for Health and Clinical Excellence (2011) Hypertension: clinical management of primary hypertension in adults. NICE Clinical Guidance 127. London: National Institute for Health and Clinical Excellence.
101. Ortiz A. Milardo L. Decarr L. Buckholz T. Mays M. Claus T. et al. (2007) A novel long-acting selective neuropeptide Y 2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J Pharmacol Exp Ther 323: 692–700.
102. Pan X. Li G. Hu Y. Wang J. Yang W. An Z. et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537–544.
103. Patel A., ADVANCE Collaborative Group, MacMahon S. Chalmers J. Neal B. Woodward M. et al. (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829–840.
104. Pi-Sunyer F. Aronne L. Heshmati H. Devin J. Rosenstock J. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761–775.
105. Pories W. Swanson M. MacDonald K. Long S. Morris P. Brown B. et al. (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222: 339–350; discussion 350–352.
106. Putz Z. Tabak A. Toth N. Istenes I. Nemeth N. Gandhi R. et al. (2009) Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 32: 181–183.
107. Ramachandran A. Snehalatha C. Mary S. Mukesh B. Bhaskar A. Vijay V. (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49: 289–297.
108. Ramachandran A. Snehalatha C. Samith Shetty A. Nanditha A. (2012) Predictive value of HbA(1c) for incident diabetes among subjects with impaired glucose tolerance-analysis of the Indian Diabetes Prevention Programmes. Diabet Med. 29: 94–98.
109. Rathmann W. Kowall B. Heier M. Herder C. Holle R. Thorand B. et al. (2010) Prediction models for incident type 2 diabetes mellitusin the older population: KORA S4/F4 cohort study. Diabet Med, 27, 1116–23.
110. Ratner R. Christophi C. Metzger B. Dabelea D. Bennett P. Pi-Sunyer X. et al. (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 93: 4774–4779.
111. Ridker P. Danielson E. Fonseca F. Genest J. Gotto A. Jr. Kastelein J. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
112. Romeo G. Lee J. Shoelson S. (2012) Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 32: 1771–1776.
113. Rosenstock J. Hollander P. Chevalier S. Iranmanesh A. (2008) SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB 1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31: 2169–2176.
114. Rubino F. Forgione A. Cummings D. Vix M. Gnuli D. Mingrone G. et al. (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244: 741–749.
115. Rubino F. Gagner M. Gentileschi P. Kini S. Fukuyama S. Feng J. et al. (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240: 236–242.
116. Rubino F. Kaplan L.M. Schauer P.R. Cummings D.E. 2010. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 251: 399–405.
117. Rubio M. Gargallo M. Isabel Millan A. Moreno B. (2007) Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr 10: 1200–1205.
118. Rucker D. Padwal R. Li S. Curioni C. Lau D. (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194–1199.
119. Rutter M. Nesto R. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 32: 2247–2255.
120. Ryden L. Standl E. Bartnik M. van den Berghe G. Betteridge J. de Boer M. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136.
121. Saito T. Watanabe M. Nishida J. Izumi T. Omura M. Takagi T. et al. (2011) Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 171: 1352–1360.
122. Salpeter S. Buckley N. Kahn J. Salpeter E. (2008) Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121: 149–157 e2.
123. Sampson U. Linton M. Fazio S. (2011) Are statins diabetogenic? Curr Opin Cardiol 26: 342–347.
124. Sartor G. Schersten B. Carlstrom S. Melander A. Norden A. Persson G. (1980) Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29: 41–49.
125. Sattar N. McConnachie A. Ford I. Gaw A. Cleland S. Forouhi N. et al. (2007) Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 56: 984–991.
126. Sattar N. Preiss D. Murray H. Welsh P. Buckley B. de Craen A. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735–742.
127. Sattar N. Taskinen M. (2012) Statins are diabetogenic–myth or reality? Atheroscler Suppl 13: 1–10.
128. Scheen A. (1999) CAPPP trial. Captopril Prevention Project. Lancet 353: 1793–1794; author reply 1795–1796.
129. Scheen A. (2004 a) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30: 487–496.
130. Scheen A. (2004 b) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30: 498–505.
131. Scheen A. (2009) Voglibose for prevention of type 2 diabetes mellitus. Lancet 373: 1579–1580.
132. Scheen A. Finer N. Hollander P. Jensen M. van Gaal L. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660–1672.
133. Shaw J. Hodge A. de Courten M. Chitson P. Zimmet P. (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42: 1050–1054.
134. Sherwin R. Anderson R. Buse J. Chin M. Eddy D. Fradkin J. et al. (2004) Prevention or delay of type 2 diabetes. Diabetes Care 27(Suppl. 1): S47–S54.
135. Singleton J. Smith A. Bromberg M. (2001) Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 24: 1448–1453.
136. Sjostrom L. Lindroos A. Peltonen M. Torgerson J. Bouchard C. Carlsson B. et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683–2693.
137. Sjostrom L. Narbro K. Sjostrom C. Karason K. Larsson B. Wedel H. et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752.
138. Skyler J. Bergenstal R. Bonow R. Buse J. Deedwania P. Gale E. et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32: 187–192.
139. Smith S. Weissman N. Anderson C. Sanchez M. Chuang E. Stubbe S. et al. (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363: 245–256.
140. Stamler J. Wentworth D. Neaton J. (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823–2828.
141. Stancakova A. Kuulasmaa T. Paananen J. Jackson A. Bonnycastle L. Collins F. et al. (2009) Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 58: 2129–2136.
142. Tabak A. Herder C. Rathmann W. Brunner E. Kivimaki M. (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379: 2279–2290.
143. Tabak A. Jokela M. Akbaraly T. Brunner E. Kivimaki M. Witte D. (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373: 2215–2221.
144. Tam J. Vemuri V. Liu J. Batkai S. Mukhopadhyay B. Godlewski G. et al. (2010) Peripheral CB 1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 2953–2966.
145. Tapp R. Shaw J. Harper C. de Courten M. Balkau B. McCarty D. et al. (2003) The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 26: 1731–1737.
146. Tapp R. Shaw J. Zimmet P. Balkau B. Chadban S. Tonkin A. et al. (2004) Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 44: 792–798.
147. Tavakoli M. Petropoulos I. Malik R. (2012) Assessing corneal nerve structure and function in diabetic neuropathy. Clin Exp Optom 95: 338–347.
148. Taylor D. (2009) Withdrawal of Rimonabant–walking the tightrope of 21st century pharmaceutical regulation? Curr Drug Saf 4: 2–4.
149. Tesfaye S. Boulton A. Dyck P. Freeman R. Horowitz M. Kempler P. et al. (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285–2293.
150. Tirosh A. Shai I. Tekes-Manova D. Israeli E. Pereg D. Shochat T. et al. (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353: 1454–1462.
151. Tominaga M. Eguchi H. Manaka H. Igarashi K. Kato T. Sekikawa A. (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920–924.
152. Toplak H. Ziegler O. Keller U. Hamann A. Godin C. Wittert G. et al. (2005) X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 7: 699–708.
153. Topol E. Bousser M. Fox K. Creager M. Despres J. Easton, J.et al. 2010. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376: 517–523.
154. Tuomilehto J. Lindstrom J. Eriksson J. Valle T. Hamalainen H. Ilanne-Parikka P. et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.
155. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.
156. Unwin N. Shaw J. Zimmet P. Alberti K. (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708–723.
157. Uusitupa M. Peltonen M. Lindstrom J. Aunola S. Ilanne-Parikka P. Keinanen-Kiukaanniemi S. et al. (2009) Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study–secondary analysis of the randomized trial. PloS ONE, 4: e5656.
158. van Gaal L. (2005) What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl 7: L21–L26.
159. van Gaal L. Rissanen A. Scheen A. Ziegler O. Rossner S. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389–1397.
160. Vettor R. Serra R. Fabris R. Pagano C. Federspil G. (2005) Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 28: 942–949.
161. Vinik A. Ziegler D. (2007) Diabetic cardiovascular autonomic neuropathy. Circulation 115: 387–397.
162. Walker E. Molitch M. Kramer M. Kahn S. Ma Y. Edelstein S. et al. (2006) Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29: 1997–2002.
163. Weir G. Bonner-Weir S. (2004) Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53(Suppl. 3): S16–S21.
164. Wierzbicki A. Hubbard J. Botha A. (2011) A renaissance for cardiometabolic surgery: better outcomes and lower costs. Int J Clin Pract 65: 728–732.
165. Wilson P. Meigs J. Sullivan L. Fox C. Nathan D. D'Agostino R. Sr. (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167: 1068–1074.
166. World Health Organization and International Diabetes Foundation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO / IDF consultation. Geneva: World Health Organisation.
167. World Health Organisation (2009). Unhealthy diets and physical inactivity. Available at http://www.who.int/nmh/publications/fact_sheet_diet_en.pdf (accessed 20 June 2013).
168. Wu J. Yang Y. Lin T. Huang Y. Chen J. Lu F. et al. (2007) Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab 92: 3885–3889.
169. Yang W. Lin L. Qi J. (2001) The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentre prospective study. Chin J Endocrinol Metab 17: 131–136.
170. Yusuf S. Sleight P. Pogue J. Bosch J. Davies R. Dagenais G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145–153.